Intervention

Guardant Reveal

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting1

Common conditions18

Lead sponsors shown2

Clinical trials

2 shown

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationNCT05059444 · 2021-09-07

Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA TestingNCT07802626 · 2026-10-30

NOT_YET_RECRUITING

Common conditions

Bladder Carcinoma1 Colon Adenocarcinoma1 Cutaneous Melanoma1 Endometrial Carcinoma1 Epithelial Ovarian Carcinoma1 Esophageal Carcinoma1 Fallopian Tube Carcinoma1 Gastric Adenocarcinoma1 Gastroesophageal Junction Carcinoma1 HR Positive/HER-2 Negative Breast Cancer1 Invasive Breast Carcinoma1 Non-small Cell Lung Cancer1 Pancreatic Adenocarcinoma1 Rectal Adenocarcinoma1 Renal Cell Carcinoma1 Renal Pelvis Carcinoma1 Squamous Cell Carcinoma of the Head and Neck1 Ureter Carcinoma1

Leading sponsors

Guardant Health, Inc.1 SWOG Cancer Research Network1

Trial status mix

NOT_YET_RECRUITING1

RECRUITING1

Phase mix

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.